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Abstract
A recent study demonstrated that vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) activate Raf-1 kinase in an experimental neovasculature system. The study
showed that bFGF and VEGF activate p21-activated protein kinase-1 (PAK-1) and Src kinase,
respectively. PAK-1 and Src kinases phosphorylate specific serine and tyrosine residues within the
activation loop of Raf-1 kinase. Their findings further suggest that phosphorylation at these sites
protects endothelial cells from apoptosis induced by both intrinsic and extrinsic factors. The tumor
neovasculature provides specific molecular markers or "zip codes". This group of investigators has
previously shown that nanosphere-aided targeting of the neovasculature with mutant Raf-1 causes
regression of the tumor vasculature. Thus, nanoparticles coated with "zip code"-specific homing
biomolecules may be useful for delivering anti-angiogenic molecules that can induce tumor
regression.
Introduction
For tumors to survive, grow and disseminate, they must be
able to secrete critical growth factors and cytokines. It is
estimated that 15 to 20 different cytokines are secreted by
various tumors. These cytokines determine the character-
istics and behaviors of many solid tumors. Some of these
cytokines can positively influence neovascularization or
angiogenesis, and others negatively regulate this process.
It is thought that an "angiogenic switch", or the balance
between positive and negative regulators, regulates the
process of angiogenesis. The neovascularization process
ultimately serves as a conduit to bring in nutrients that
promote growth and metastasis [1]. Thus, the angiogenic
switch also determines tumor cell growth. Many of these
cytokines are also used under normal physiological condi-
tions in various cells and tissues; therefore, direct interfer-
ence with these cytokines is not a viable option. It has
been recently shown that signaling events mediated by
bFGF in endothelial cells targets Raf-1 to the mitochon-
dria, which protects these cells from apoptosis [2]. This
provides a mechanism that effectively explains why target-
ing the tumor neovasculature with a mutant Raf-1 gene
exerts anti-angiogenic effects [3].
Discussions
Basic FGF and VEGF are survival factors
A number of cytokines and growth factor polypeptides
have been shown to act as survival factors during angio-
genesis, including the acidic and basic fibroblast growth
factors (FGFs) and vascular endothelial growth factor
(VEGF). Basic FGF (bFGF) and VEGF are two of the
cytokines that have been most widely studied, because of
their ability to induce many physiological responses,
including survival and tumor growth. Both in vitro and in
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vivo studies suggest that these mediators play a role in ang-
iogenesis. These studies showed that bFGF and VEGF
induce mitogenesis and capillary morphogenesis. Further-
more, these factors and their receptors are up-regulated
under ischemic conditions in vivo, and administration of
these proteins in vivo enhances capillary morphogenesis
[1]. The intracellular signaling components regulated by
these cytokines have been studied both in cultured cells
and in vivo. The production of VEGF by tumors is known
occur in response to various upstream factors, including
hypoxia, elevated concentrations of bFGF, epidermal
growth factor (EGF), insulin-like growth (IGF) and hydro-
gen peroxide (H2O2) (Figure 1). Several lines of evidence
show that VEGF is one of the most important factors in
tumor cell survival and neovascularization [4]. For exam-
ple, deletion of VEGF or its receptor in mice results in the
loss of functional blood vessels and early embryonic
lethality [4]. Furthermore, blocking VEGF or VEGF recep-
tor functions can induce regression of tumor vasculature
in vivo [1,4].
How do tumors survive, grow and become resistant to drug treatment? The answer may lie in the fact that tumors secrete  multiple cytokines and growth factors Figure 1
How do tumors survive, grow and become resistant to drug treatment? The answer may lie in the fact that tumors secrete 
multiple cytokines and growth factors. A complex interplay between positive and negative factors determines the survival of 
tumors. The apoptotic signals exerted by "intrinsic" and "extrinsic" pathways could be rescued by bFGF and VEGF. These 
cytokines activate the PAK-1 and Src kinases, and phosphorylation of specific amino acid residues (indicated by the lightning 
symbols) within the Raf-1 kinase signals it to be targeted to the mitochondria, which promotes endothelial cell survival 
[adapted from Alavi, A. et al., Science 301; 94–6 (2003)].
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Signaling through Raf-1 kinase
VEGF and bFGF act through specific cell surface receptor
tyrosine kinases, which both utilize the canonical Ras/
Raf/Mitogen-activated protein kinase (MAP) / extracellu-
lar-signal-regulated kinase (ERK) signaling events that
link growth factor receptors to nuclear events. The Raf sig-
naling pathway has been highly conserved throughout
evolution, and activation of the Raf protein kinase is con-
sidered to be a primary event in the Ras signaling pathway
[5]. Depending on the specific stimulus and cell type
involved, this signaling pathway can promote cell sur-
vival, proliferation, or apoptosis. The Raf genes encode
cytoplasmic protein serine/threonine kinases that play a
critical role in cell growth and differentiation [6]. There
are three Raf genes, c-Raf (Raf-1), A-Raf and B-Raf. The
expression of A-Raf and B-Raf are known to be somewhat
restricted. Structural and functional studies have shown
that Raf is composed of two distinct domains, an N-termi-
nal Ras interacting domain and a C-terminal serine/threo-
nine kinase domain. The GTP-bound form of Ras directly
interacts with N-terminal region of Raf-1 (Figure 1). This
binding localizes Raf to the plasma membrane. Targeting
of Raf-l to mitochondria links Ras to a cell survival path-
way [7,8]. The binding of Raf-1 to Ras is not sufficient to
promote its activation. Raf-1 has been shown to be phos-
phorylated on tyrosines 340 and 341, as well as on serines
43, 259, 499, and 621 and threonine 269. Intracellular
protein tyrosine kinase Src has been implicated in the
tyrosine phosphorylation of Raf-1 [8,9]. Phorbol ester is
also known to induce phosphorylation of serine 259 and
499. Another recent study suggested that phosphorylation
of threonine 491 and serine 494, two phosphorylation
sites within the catalytic domain of Raf-1, may be required
for its activation, but not inhibition [10]. While these
phosphorylation events positively regulate Raf-1 activity,
phosphorylation induced by protein kinase A and possi-
bly ERK may negatively impact Raf-1 functions [8].
Targeting of Raf-1 to mitochondria protects endothelial 
cells from apoptosis
Recently, Alavi et al. demonstrated that bFGF and VEGF
utilize the same target, i.e. Raf-1, kinase with distinct spe-
cificity [2]. In this elegant study, Alavi et al. examined the
role of bFGF-and VEGF-induced activation of p21-acti-
vated protein kinase-1 (PAK-1) and Src kinase in the acti-
vation of Raf-1 kinase. Both cytokines induced activation
of Focal adhesion kinase (FAK) and ERK, but only bFGF-
induced phosphorylation of serines 338 and 339 pro-
moted endothelial cell survival. Serum starvation or DNA
damage (intrinsic pathway) induced apoptosis. This path-
way requires the action of bFGF through PAK-1 kinase,
which directly phosphorylates the serine 338 and 339 res-
idues of Raf-1 and targets it to the mitochondria (Figure
1). Once in the mitochondria, Bcl-2 mediated anti-apop-
totic mechanisms promote cell survival. In contrast to the
effects of bFGF, VEGF induced Src-mediated phosphoryla-
tion of tyrosines 340 and 341. This required activation of
MEK-1 and ERK1/2, and conferred protection of endothe-
lial cell against apoptosis induced by exposure to tumor
necrosis factor (extrinsic pathway) [2]. It appears that a
loss-of-function mutant form of Raf-1 i.e., Raf-1 SS338/
339AA+YY340/341FF blocks both bFGF- and VEGF-medi-
ated protection of endothelial cells against 'intrinsic' and
'extrinsic' apoptotic events. Based on this study, it will be
of considerable interest to investigate the regulation of
Raf-1 kinase in response to EGF, IGF and platelet-derived
growth factor (PDGF), and to examine how these growth
factors affect endothelial cell survival. Furthermore, it will
also be important to evaluate the role of adhesion recep-
tors  αvβ3 and  α5β1 integrins in the regulation of Raf-1
kinase activity.
Conclusions
Previously Hood et al. showed that the nanocrystal-aided
targeting of the neovasculature with mutant Raf-1 exerts
anti-angiogenic effects [3,11]. Taken together with the
recent work by Alavi et al. [2], these studies suggest new
possibilities for targeting the tumor neovasculature with
small molecule drugs directed against Raf-1 that could
promote the apoptosis of endothelial cells and cause
regression of tumor vasculature. Endothelial cell death
also plays a key role in myocardial infarction and heart
failure. These studies also suggest opportunities for induc-
ing therapeutic angiogenesis, in tissues where unwanted
apoptosis could be prevented by promoting the transloca-
tion of activated Raf-1 kinase into the mitochondria.
Taken together, these studies clearly bring nanotechnol-
ogy-aided anti-angiogenic molecular therapeutics a step
closer to reality.
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